Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGunsynd Regulatory News (GUN)

Share Price Information for Gunsynd (GUN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.13
Bid: 0.12
Ask: 0.14
Change: 0.00 (0.00%)
Spread: 0.02 (16.667%)
Open: 0.13
High: 0.13
Low: 0.13
Prev. Close: 0.13
GUN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Horse Hill Update

3 Aug 2018 11:30

RNS Number : 7926W
Gunsynd PLC
03 August 2018
 

 

Gunsynd PLC

("Gunsynd" or the "Company")

 

Completion of Portland High Rate Flow Test

 Horse Hill-1 ("HH-1") oil discovery, Weald Basin, UK

 

Highlights:

 

· Portland short-term high rate tests achieve stable implied equivalent daily pumped rates of 401 and 414 barrels of oil per day ("bopd") of dry 36 API oil over two periods of 6 and 2 hours, respectively. Maximum instantaneous half-hourly pumped rates of 441 and 470 bopd.

· The maximum rate recorded was limited by the rod pump's maximum rate capacity of approximately 470 bopd. Higher capacity rod pump sourced and mobilised for use at HH-1.

· Metered daily oil rates and recovered Portland volumes, to date, exceed 2016 test values.

· Associated solution gas rates of around 41,000 cu ft per day.

· Forward extended well test ("EWT") programme includes flow optimisation necessary to determine the maximum sustainable long-term flow rate and a lengthy stabilised flow period to test whether the well accesses a commercially viable oil volume.

· The primary EWT objective, to establish the commerciality of the Kimmeridge Limestone 3 & 4 oil pools, will follow directly after the completion of the Portland test sequence.

Gunsynd (London AIM: PRIM) announces that Horse Hill Developments Ltd, the operator of the HH-1 Kimmeridge and Portland oil discovery, located in licence PEDL137, in which Gunsynd holds a 1.3% beneficial interest, has informed the Company that the planned high rate Portland test sequence, designed to assess the reservoir's maximum short-term flow capacity, has been successfully completed. Stable implied daily pumped rates of 401 and 414 bopd of dry 36 API oil were recorded over two periods of 6 and 2 hours, respectively, with associated maximum half-hourly pumped rates of 441 and 470 bopd. Metered solution gas rates of around 41,000 cu ft per day were recorded through the test separator over the two maximum rate periods.

As maximum initial rates were restricted by the pump's capacity of around 470 bopd, a larger capacity pump has been sourced and has been mobilised to site for possible use during the remainder of the Portland test sequence.

To date, the recorded implied daily oil rates and overall produced Portland oil volumes exceed those reported from the initial short-term test programme of March 2016. The "dry" Portland oil exported from the HH-1 EWT to date is of Brent Crude quality and exceeds minimum refinery specifications, containing only around 0.2% water content.

It should be noted that the above high rate results are not the long-term sustainable flow rates that will be utilised to assess the Portland's commercial viability as part of the next test phase.

Forward EWT Plans

 

Following a planned further short restricted flow period and pressure build up test, flow will be further optimised to determine the well's sustainable long-term production rate and to test whether the well can recover a commercially viable volume of oil.

The primary EWT objective of testing the two underlying Kimmeridge Limestone 3 & 4 oil pools, which in 2016 flowed 40 API crude naturally to surface at an aggregate implied stable dry oil rate of 1,365 bopd, will commence directly after completion of the Portland test.

Further updates will be provided as the EWT progresses.

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 

The directors of Gunsynd accept responsibility for this announcement.

 

For further information, please contact:

 

Gunsynd plc

Hamish Harris

 

+44 20 7440 0640

Cairn Financial Advisers LLP

James Caithie / Liam Murray

 

+44 20 7213 0880

Peterhouse Corporate Finance

Lucy Williams

 

+44 20 7469 0930

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGUMGRUPRGUW
Date   Source Headline
6th Dec 20129:57 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20127:00 amRNSApproval of Opening Position Disclosure
5th Dec 201211:11 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 201211:53 amRNSForm 8.5 (EPT/NON-RI)
3rd Dec 201212:19 pmRNSForm 8.3 - [Evocutis PLC]
3rd Dec 20127:00 amRNSStrategic Review
3rd Dec 20127:00 amRNSFinal Results
23rd Nov 20127:00 amRNSNotice of Results
5th Nov 20127:00 amRNSIssue of Equity
21st Sep 20127:00 amRNSTR-1 Notification of Major Interest in Shares
8th Aug 201212:24 pmRNSUpdate on commencement of dealings
1st Aug 20127:00 amRNSIssue of Equity and Grant of Share Options
21st Jun 20127:00 amRNSTrading Update
30th Apr 20127:00 amRNSDirectorate Change
4th Apr 20127:00 amRNSDirectorate Change
22nd Mar 20127:00 amRNSInterim Results
29th Feb 20127:00 amRNSNotification of Results
27th Jan 20127:00 amRNSEvocutis validates anti-ageing LabSkinT model
24th Jan 20121:35 pmRNSResult of AGM
13th Jan 20127:00 amRNSEvocutis Opens State-of-the-art laboratory
23rd Dec 20117:00 amRNSDirector/PDMR Shareholding
15th Dec 20117:00 amRNSNotice of AGM and Report and Accounts
29th Nov 20117:00 amRNSPreliminary Results
28th Nov 20117:00 amRNSEvocutis launches antimicrobial LabSkinT model
20th Oct 20115:03 pmRNSResult of GM and Change of Name to Evocutis plc
30th Sep 20117:00 amRNSBusiness Update
27th Sep 20117:00 amRNSPosting of Circular and Notice of General Meeting
8th Jul 20117:00 amRNSChange of Registered Office
21st Jun 201111:00 amRNSDirectorate Change
23rd May 201111:45 amRNSResult of General Meeting
11th May 201111:17 amRNSDirector's Dealing
6th May 20117:00 amRNSAcquisition and Placing to raise £2 million
27th Apr 20112:30 pmRNSBusiness Update
8th Mar 20117:00 amRNSInterim Results
2nd Mar 20113:12 pmRNSHolding(s) in Company
25th Feb 20117:00 amRNSHolding(s) in Company
20th Jan 20111:23 pmRNSResult of AGM
17th Jan 20117:00 amRNSSyntopix to research biofilms for Beiersdorf AG
14th Jan 201110:13 amRNSPosting of Annual Report and notice of AGM
3rd Dec 20107:00 amRNSGrant of share options to Directors
29th Nov 20107:00 amRNSFinal Results
11th Nov 20107:00 amRNSAppointment of Broker
1st Nov 20107:00 amRNSSecond Agreement with Sinclair Pharma
29th Sep 20105:05 pmRNSHolding(s) in Company
27th Sep 20102:51 pmRNSHolding(s) in Company
23rd Aug 20107:00 amRNSAgreement with Global Consumer Products Company
22nd Jun 20103:20 pmRNSDirectorate Change
22nd Apr 20107:00 amRNSAgreement with Sinclair Pharma plc
31st Mar 201011:25 amRNSResult of General Meeting
15th Mar 201011:08 amRNSProposed Fundraising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.